摘要
目的探讨对冠心病患者予以阿托伐他汀联合曲美他嗪治疗的效果。方法纳入时间为2014年3月-2019年3月,在医院收治的冠心病患者中选取60例,依照计算机表法分组,各30例。将采取阿托伐他汀治疗的冠心病患者作为参照组,将采取阿托伐他汀联合曲美他嗪治疗的冠心病患者作为实验组。计算2组冠心病患者的炎性因子水平、心功能水平以及血脂水平。结果治疗前2组冠心病患者的炎性因子水平、心功能水平以及血脂水平经对比组间差异性不明显(P>0.05);治疗后实验组冠心病患者的甘油三酯、总胆固醇水平低于参照组,实验组冠心病患者的左室舒张末期内径、左室射血分数明显优于参照组,实验组冠心病患者的白细胞介素-6、肿瘤坏死因子-a、血清超敏C反应蛋白水平均低于参照组,组间差异性显著(P <0.05)。结论对冠心病患者予以阿托伐他汀联合曲美他嗪治疗,使患者的血脂水平明显下降,其心功能指标明显提升,使患者的机体炎症得到明显缓解,临床治疗安全性较高。
Objective To investigate the effect of atorvastatin combined with trimetazidine on patients with coronary heart disease. Methods From March 2014 to March 2019, 60 patients with coronary heart disease admitted to our hospital were selected and grouped according to the method of computer table, 30 cases each. Patients with coronary heart disease treated with atorvastatin were used as the reference group, and patients with coronary heart disease treated with atorvastatin combined with trimetazidine were used as the experimental group. The levels of inflammatory factors,cardiac function and blood lipid in 2 groups of patients with coronary heart disease were calculated. Results Before treatment, there was no significant difference in inflammatory factors, cardiac function and lipid levels between the two groups(P > 0.05). Experimental group after treatment in patientswith coronary heart disease of triglyceride, total cholesterol level is lower than the control group, experimental group coronary heart disease(CHD)patients with left ventricular end-diastolic diameter, left ventricular ejection fraction was better than control group, experimental group coronary heart disease(CHD) in patients with interleukin 6 and tumor necrosis factor-a and serum hypersensitive c-reactive protein levels are lower than the control group, the differences between group significantly(P < 0.05). Conclusion The treatment of atorvastatin combined with trimetazidine in patients with coronary heart disease can significantly decrease the level of blood lipid,significantly improve the cardiac function index, and significantly relieve the inflammation in patients with coronary heart disease.
作者
娄红超
LOU Hongchao(Department of Geriatrics,Suzhou Kowloon Hospital Affiliated to School of Medicine of Shanghai Jiaotong University,Suzhou Jiangsu 215021,China)
出处
《中国继续医学教育》
2019年第36期133-135,共3页
China Continuing Medical Education
关键词
冠心病
阿托伐他汀
曲美他嗪
安全性
血脂水平
心功能水平
coronary heart disease
Atorvastatin
trimetazidine
security
blood lipid level
cardiac function level
